Scalper1 News
A day after Teva Pharmaceuticals (TEVA) broke out of a base, fellow drugmaker Amgen (AMGN) is clearing a buy point. Amgen reports second quarter results after the close on Thursday. Earnings are projected to rise 3%, a slowdown from the first quarter’s 33% growth. The stock climbed in big volume in the stock market today, clearing an early buy point of 165.50. Amgen is also nearing a conventional buy point of 173.70. It’s currently trading about Scalper1 News
Scalper1 News